Want to see FEMY full AI Analyst Report?
Top Page
Femasys
(NASDAQ:FEMY)
Select Model
Select Model
Rating:45Neutral
Price Target:
$4.00
▲(447.95% Upside)
Action:Reiterated
Date:06/25/26
The score is primarily held down by weak financial performance—very large losses and persistent, sizable cash burn despite improving revenue and solid gross margins. Technicals add additional pressure due to a strong downtrend, partially offset by oversold indicators. Corporate events modestly improve the outlook by reducing listing risk and strengthening leadership, while valuation is constrained by continued unprofitability.
Positive Factors
Sustained Revenue Growth
Revenue growth across multiple years shows the company is gaining commercial traction with clinicians and expanding product adoption. This durable top-line improvement supports scaling opportunities, incremental operating leverage potential, and validates the market need for its women’s health diagnostics and related consumables.
Negative Factors
High and Persistent Cash Burn
Large, sustained negative operating and free cash flow indicate the business is not yet self-funding and requires ongoing external capital. Over months this pressure constrains strategic flexibility, risks delaying commercialization investments, and forces management to prioritize financing over long-term R&D or go-to-market programs.
Read all positive and negative factors
Positive Factors
Negative Factors
Sustained Revenue Growth
Revenue growth across multiple years shows the company is gaining commercial traction with clinicians and expanding product adoption. This durable top-line improvement supports scaling opportunities, incremental operating leverage potential, and validates the market need for its women’s health diagnostics and related consumables.
Read all positive factors
Femasys (FEMY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$12.05M
Dividend YieldN/A
Average Volume (3M)53.85K
Price to Earnings (P/E)―
Beta (1Y)0.88
Revenue Growth39.88%
EPS Growth64.70%
CountryUS
Employees54
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)-6.43
Shares Outstanding3,019,534
10 Day Avg. Volume29,931
30 Day Avg. Volume53,850
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)3.88
Price to Sales (P/S)9.93
P/FCF Ratio-1.19
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue5.05
Enterprise Value/Gross Profit9.50
Enterprise Value/Ebitda-1.27
Forecast
1Y Price Target
$30.00Price Target Upside4009.59% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-4.53
Revenue Forecast (FY)$3.77M
Femasys Business Overview & Revenue Model
Company Description
Femasys Inc., a biomedical company established in 2004 and based in Suwanee, Georgia, primarily targets the women's healthcare market within the United States. The firm's innovative product line includes permanent contraceptive solutions such as F...
How the Company Makes Money
Femasys makes money primarily by selling and distributing its women’s health medical products to healthcare providers and clinical facilities. A key revenue stream is product revenue generated from the sale of FemVue and related consumables used i...
Femasys Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
54
Neutral
Cash Flow
16
Very Negative
| Breakdown | Mar 2026 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.29M | 1.63M | 1.07M | 1.21M | 1.18M |
| Gross Profit | 1.42M | 1.08M | 691.90K | 764.28K | 809.30K |
| EBITDA | -15.89M | -16.33M | -13.17M | -10.49M | -6.55M |
| Net Income | -18.63M | -18.82M | -14.25M | -11.39M | -7.54M |
Balance Sheet | |||||
| Total Assets | 20.72M | 12.45M | 27.76M | 16.90M | 28.58M |
| Cash, Cash Equivalents and Short-Term Investments | 9.27M | 3.45M | 21.72M | 12.96M | 24.78M |
| Total Debt | 4.70M | 7.44M | 6.70M | 543.72K | 990.21K |
| Total Liabilities | 14.85M | 10.14M | 9.40M | 1.65M | 2.24M |
| Stockholders Equity | 5.87M | 2.30M | 18.35M | 15.24M | 26.33M |
Cash Flow | |||||
| Free Cash Flow | -19.22M | -20.21M | -11.42M | -11.14M | -8.24M |
| Operating Cash Flow | -18.69M | -19.44M | -11.28M | -10.73M | -7.93M |
| Investing Cash Flow | -630.10K | -847.76K | -143.92K | -407.48K | -306.87K |
| Financing Cash Flow | 25.14M | 2.03M | 20.18M | -681.64K | 29.70M |
Femasys Technical Analysis
Negative
0.73
Price Trends
5.96
Negative
7.83
Negative
10.72
Negative
Market Momentum
-0.60
Negative
31.77
Neutral
20.10
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FEMY, the sentiment is Negative. The current price of 0.73 is below the 20-day moving average (MA) of 3.95, below the 50-day MA of 5.96, and below the 200-day MA of 10.72, indicating a bearish trend. The MACD of -0.60 indicates Negative momentum. The RSI at 31.77 is Neutral, neither overbought nor oversold. The STOCH value of 20.10 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FEMY.
Femasys Risk Analysis
Femasys disclosed 78 risk factors in its most recent earnings report. Femasys reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Femasys Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $54.51M | -7.23 | -37.47% | ― | 64.18% | 28.90% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $20.51M | -3.18 | -8.13% | ― | 10.08% | 71.71% | |
45 Neutral | $12.05M | -0.54 | -258.08% | ― | 39.88% | 64.70% | |
45 Neutral | $33.78M | -7.07 | -166.28% | ― | 3.37% | 15.78% | |
45 Neutral | $6.12M | -1.19 | -55.33% | ― | 10.14% | 12.18% |
* Healthcare Sector Average
FEMY
Femasys
3.47
-15.33
-81.54%
RVP
Retractable Technologies
0.69
0.02
2.24%
MLSS
Milestone Scientific
0.39
-0.26
-39.38%
POCI
Precision Optics Corporation
4.80
-0.02
-0.41%
NXGL
NexGel Inc
0.47
-2.08
-81.53%
Femasys Corporate Events
Executive/Board ChangesShareholder Meetings
Femasys Shareholders Approve Directors and Auditor at Meeting
Positive
Jun 24, 2026
Femasys Inc. held its Annual Meeting of Stockholders on June 24, 2026, with approximately 49.26% of eligible common shares represented in person, virtually, or by proxy. At the meeting, shareholders approved the election of two Class II directors,...
Business Operations and StrategyDelistings and Listing ChangesRegulatory Filings and ComplianceStock Split
Femasys Regains Nasdaq Compliance After Reverse Stock Split
Positive
Jun 24, 2026
On June 23, 2026, Femasys Inc. said it regained compliance with Nasdaq’s minimum bid price requirement for the Capital Market, closing a deficiency first flagged by the exchange in July 2025. The company met the $1.00 per share standard afte...
Delistings and Listing ChangesShareholder MeetingsStock Split
Femasys Announces 1-for-20 Reverse Stock Split Implementation
Neutral
Jun 5, 2026
On June 5, 2026, Femasys Inc. implemented a 1-for-20 reverse stock split of its common shares, following stockholder authorization at a special meeting held on April 29, 2026. Every 20 shares of issued and outstanding common stock were automatical...
Business Operations and StrategyStock Split
Femasys Announces 1-for-20 Reverse Stock Split Initiative
Neutral
Jun 4, 2026
On June 4, 2026, Femasys Inc. announced a 1-for-20 reverse stock split of its common stock, effective at 4:30 p.m. Eastern Time on June 5, 2026, with trading on a split-adjusted basis to begin on June 8, 2026 under the existing ticker FEMY and a n...
Business Operations and StrategyRegulatory Filings and Compliance
Femasys updates corporate presentation on women’s health portfolio
Positive
May 13, 2026
On May 13, 2026, Femasys Inc. posted an updated corporate slide presentation on its website, intended for use in ongoing meetings with investors, analysts and other stakeholders. The materials highlight the company’s diversified women’...
Private Placements and FinancingRegulatory Filings and ComplianceShareholder MeetingsStock Split
Femasys Shareholders Approve Reverse Split and Financing Plans
Neutral
Apr 29, 2026
At a special meeting of stockholders held on April 29, 2026, Femasys Inc. shareholders approved an amendment to the company’s certificate of incorporation authorizing a reverse stock split of its common shares at a ratio between 1-for-2 and ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.